AstraZeneca PLC (AZN)

NYSE: AZN · Pharmaceutical Preparations · Cambridge · filing with the SEC since 1995

Full chart Alerts Compare

Grade6.8

◀ Past 7.8● Present 7.0▶ Future 5.5

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of AstraZeneca PLC

Nine metrics read from its own filings, by tense

Headline grade

6.8/10

◀ Past7.830% of the headline

● Present7.040% of the headline

▶ Future5.530% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.8/1030% of the headline grade · 3 of 3 filed

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

AstraZeneca PLC's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

7.3/10

What has it actually done, year after year?

+11% a year over 10 filed years; profitable in 10 of 10.

weight 45% of this tense · 73rd percentile among 323 sector filers · read for its customers

From the record

AstraZeneca PLC's 10 filed years say what it did: revenue went from $23 billion in fiscal 2016 to $59 billion in fiscal 2025, up 11% a year; it rose in 7 of 9 years; the deepest fall was 4% from fiscal 2016 to fiscal 2018; net income was positive in 10 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span11.0%bottom 47% of its family
the share of years revenue rosetop 28% of its family
the share of filed years with a profittop 3% of its family
the deepest fall from a revenue peak4.0%top 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed

8.1/10

How has it treated the people who own it?

Share count steady. 40% of cash flow returned. Insiders: 1 sales, 1 purchases.

weight 22% of this tense · 81st percentile among 80 sector filers · read for its shareholders

From the record

Over the 3 fiscal years to 2025-12-31, AstraZeneca PLC's diluted share count held steady, and dividends and buybacks returned about 40% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 1 sale and 1 purchase of their own stock on the open market in the year to 2026-11-10, buying about $3 thousand (their Form 4 filings).

What it rests on

the share count over the yearstop 11% of its family
cash returned against operating cash flowtop 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

7.0/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

7.2/10

Is it financially healthy right now?

ROE 21%: 21¢ of profit per shareholder dollar. Leverage 57%: owes 57¢ per asset dollar.

weight 45% of this tense · 72nd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, AstraZeneca PLC earned about 21 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 42 cents per dollar of everything the company owns. Leverage: it owed about 57 cents per dollar of assets, and net share issuance: its share count shrank 0.1% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 29% of its family
return on equitytop 7% of its family
gross profit against assetstop 27% of its family
the share count against the year beforetop 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

7.9/10

How strong is its position in its industry?

top 21% of 315 in its family; net margin 17.4%.

weight 33% of this tense · 79th percentile among 315 sector filers · read for its customers

From the record

AstraZeneca PLC's standing among 315 graded names in its industry family: revenue of $59 billion in fiscal 2025 ranks in the top 2% by size; a net margin of 17.4% ranks in the top 13%; revenue growth of 9.8% a year over the last 3 filed years ranks in the top 48% (its annual reports).

What it rests on

revenue against the family$58.74Btop 2% of its family
net margin17.4%top 13% of its family
three-year revenue growth9.8%top 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: AstraZeneca PLC's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.5/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.8/10

How much room does it have to grow?

bottom 48% of 273 in its family for room to expand.

weight 45% of this tense · 48th percentile among 273 sector filers · read for itself

From the record

AstraZeneca PLC's room to grow, from the newest filed statements (fiscal 2025): cash of $5.7 billion against debt of $30 billion leaves -21% of its assets as net cash, bottom 7% of its family; cash from operations less capital spending is 20% of revenue (top 12%); a gross margin of 81.9% (top 30%); research spending of 24.2% of revenue (bottom 29%) (its annual report).

What it rests on

cash less debt against assets-21.0%bottom 7% of its family
cash from operations less capital spending against revenue20.0%top 12% of its family
gross margin81.9%top 30% of its family
research spending against revenue24.2%bottom 29% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

6.2/10

What could actually drive growth from here?

top 38% of 306 in its family for growth drivers.

weight 33% of this tense · 62nd percentile among 306 sector filers · read for its customers

From the record

AstraZeneca PLC's growth drivers, from the filed years to fiscal 2025: revenue grew 9.8% a year over the last three filed years against 11% over all 10, slowing (top 50% of its family); the newest year grew 8.6% (top 49%); research spending grew 13.4% a year (top 34%); capital spending grew 37.1% a year (top 18%) (its annual reports). AstraZeneca PLC tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-1.2 points a yeartop 50% of its family
the newest year's revenue growth8.6%top 49% of its family
three-year growth of research spending13.4%top 34% of its family
three-year growth of capital spending37.1%top 18% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.9/10

Did its newest year beat what its own record pointed to?

top 41% of 233 in its family for expectations against reality.

weight 22% of this tense · 59th percentile among 233 sector filers · read for its shareholders

From the record

AstraZeneca PLC's newest year against its own record: revenue of $59 billion in fiscal 2025 came in 1.6% below the $60 billion its prior three years' pace pointed to (top 49% of its family); net income of $10 billion against a prior three-year average of $5.4 billion (top 19%); a net margin of 17.4% against 11.2% before (bottom 45%) (its annual reports).

What it rests on

revenue against the prior three years' pace-1.6%top 49% of its family
net income against the prior three years' average+88%top 19% of its family
net margin against its prior average+6.3 pointsbottom 45% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton AZN · research, not advice